ValuEngine upgraded shares of ANCHIANO THERAP/S (NASDAQ:ANCN) from a hold rating to a buy rating in a research note issued to investors on Thursday, ValuEngine reports.
A number of other brokerages have also weighed in on ANCN. Robert W. Baird started coverage on shares of ANCHIANO THERAP/S in a report on Tuesday, May 28th. They issued an outperform rating and a $12.00 price objective on the stock. Zacks Investment Research lowered shares of ANCHIANO THERAP/S from a hold rating to a sell rating in a report on Thursday, June 6th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. ANCHIANO THERAP/S has a consensus rating of Buy and a consensus target price of $14.00.
ANCHIANO THERAP/S stock traded up $0.36 during mid-day trading on Thursday, reaching $3.19. 98,706 shares of the company’s stock were exchanged, compared to its average volume of 13,455. The firm has a market capitalization of $21.00 million and a P/E ratio of -0.61. ANCHIANO THERAP/S has a twelve month low of $2.73 and a twelve month high of $11.50. The stock’s fifty day simple moving average is $4.21.
ANCHIANO THERAP/S (NASDAQ:ANCN) last released its earnings results on Wednesday, May 22nd. The company reported ($3.50) earnings per share (EPS) for the quarter. On average, equities research analysts predict that ANCHIANO THERAP/S will post -3.78 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC purchased a new stake in ANCHIANO THERAP/S during the 1st quarter valued at about $288,000. Kennedy Capital Management Inc. purchased a new stake in shares of ANCHIANO THERAP/S in the 1st quarter valued at approximately $1,359,000. Delek Group Ltd. purchased a new position in shares of ANCHIANO THERAP/S during the 1st quarter worth approximately $176,000. Finally, Meitav Dash Investments Ltd. purchased a new position in shares of ANCHIANO THERAP/S during the 1st quarter worth approximately $177,000. Institutional investors and hedge funds own 6.18% of the company’s stock.
ANCHIANO THERAP/S Company Profile
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.
Featured Story: Price to Earnings Ratio (PE)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.